TP53 and cancer: As shown in Figure 3C, p21 degradation was impaired after CDT2 depletion, but only in p53 proficient cancer cell lines (such as TOV-21G) and not in p53 defective cancer cell lines (such as SK-OV-3) and in p53 proficient non-transformed cell lines (such as MCF-10A).